NGF, nerve growth factor, 4803

N. diseases: 616; N. variants: 11
Disease: Chronic pain ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0150055
Disease: Chronic pain
Chronic pain 		0.040 Biomarker phenotype BEFREE To share learnings regarding the rigorous evaluation of clinical and nonclinical safety data which contributed to the removal of these partial clinical holds, this article reviews the rationale for developing agents that target NGF as potential treatments for chronic pain, describes nonclinical and clinical studies of these agents, and describes strategies used to evaluate whether inhibition of NGF has negative effects on joint or sympathetic nervous system safety. 29415946 2018
CUI: C0150055
Disease: Chronic pain
Chronic pain 		0.040 Biomarker phenotype BEFREE Blockade of nerve growth factor (NGF) with antibodies is a promising strategy for treatment of chronic pain associated with osteoarthritis (OA). 28967370 2017
CUI: C0150055
Disease: Chronic pain
Chronic pain 		0.040 Biomarker phenotype BEFREE Targeting the Nerve Growth Factor (NGF) Pathway in Drug Discovery. Potential Applications to New Therapies for Chronic Pain. 27779399 2017
CUI: C0150055
Disease: Chronic pain
Chronic pain 		0.040 Biomarker phenotype BEFREE Tanezumab, a humanized monoclonal antibody against nerve growth factor is in development for treatment of chronic pain. 28525647 2017